269 related articles for article (PubMed ID: 31900542)
21. Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment.
Hirooka Y; Nozaki Y; Inoue A; Li J; Shiga T; Kishimoto K; Sugiyama M; Kinoshita K; Funauchi M; Matsumura I
Bone Rep; 2020 Dec; 13():100293. PubMed ID: 32676524
[TBL] [Abstract][Full Text] [Related]
22. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
Nakamura Y; Suzuki T; Kato H
Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
[TBL] [Abstract][Full Text] [Related]
23. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.
Broadwell A; Chines A; Ebeling PR; Franek E; Huang S; Smith S; Kendler D; Messina O; Miller PD
J Clin Endocrinol Metab; 2021 Jan; 106(2):397-409. PubMed ID: 33211870
[TBL] [Abstract][Full Text] [Related]
24. Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients.
Kamimura M; Nakamura Y; Ikegami S; Uchiyama S; Kato H; Taguchi A
Osteoporos Int; 2017 Feb; 28(2):559-566. PubMed ID: 27650642
[TBL] [Abstract][Full Text] [Related]
25. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
[TBL] [Abstract][Full Text] [Related]
26. Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab.
Kobel C; Frey D; Graf N; Wüthrich RP; Bonani M
Kidney Blood Press Res; 2019; 44(5):1285-1293. PubMed ID: 31614356
[TBL] [Abstract][Full Text] [Related]
27. Hypocalcemia and bone mineral density changes following denosumab treatment in end-stage renal disease patients: a meta-analysis of observational studies.
Thongprayoon C; Acharya P; Acharya C; Chenbhanich J; Bathini T; Boonpheng B; Sharma K; Wijarnpreecha K; Ungprasert P; Gonzalez Suarez ML; Cheungpasitporn W
Osteoporos Int; 2018 Aug; 29(8):1737-1745. PubMed ID: 29713798
[TBL] [Abstract][Full Text] [Related]
28. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
29. Bisphosphonates for prevention of osteopenia in kidney-transplant recipients: a systematic review of randomized controlled trials.
Wang J; Yao M; Xu JH; Shu B; Wang YJ; Cui XJ
Osteoporos Int; 2016 May; 27(5):1683-90. PubMed ID: 26733377
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of denosumab compared to bisphosphonates in improving bone strength in postmenopausal osteoporosis: a systematic review.
Chandran T; Venkatachalam I
Singapore Med J; 2019 Jul; 60(7):364-378. PubMed ID: 30854568
[TBL] [Abstract][Full Text] [Related]
31. Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials.
Mitterbauer C; Schwarz C; Haas M; Oberbauer R
Nephrol Dial Transplant; 2006 Aug; 21(8):2275-81. PubMed ID: 16574684
[TBL] [Abstract][Full Text] [Related]
32. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
[TBL] [Abstract][Full Text] [Related]
33. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
[TBL] [Abstract][Full Text] [Related]
34. Denosumab compared to other treatments to prevent or treat osteoporosis in individuals at risk of fracture: a systematic review and meta-analysis.
Beaudoin C; Jean S; Bessette L; Ste-Marie LG; Moore L; Brown JP
Osteoporos Int; 2016 Sep; 27(9):2835-2844. PubMed ID: 27120345
[TBL] [Abstract][Full Text] [Related]
35. Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
Lyu H; Jundi B; Xu C; Tedeschi SK; Yoshida K; Zhao S; Nigwekar SU; Leder BZ; Solomon DH
J Clin Endocrinol Metab; 2019 May; 104(5):1753-1765. PubMed ID: 30535289
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of denosumab on bone metabolism and bone mineral density in renal transplant recipients: A systematic review and meta-analysis.
Zhu P; Yang T; Le J; Fu X; Zhang L
Transplant Rev (Orlando); 2023 Dec; 37(4):100793. PubMed ID: 37659288
[TBL] [Abstract][Full Text] [Related]
37. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates.
Miller PD; Pannacciulli N; Brown JP; Czerwinski E; Nedergaard BS; Bolognese MA; Malouf J; Bone HG; Reginster JY; Singer A; Wang C; Wagman RB; Cummings SR
J Clin Endocrinol Metab; 2016 Aug; 101(8):3163-70. PubMed ID: 27270237
[TBL] [Abstract][Full Text] [Related]
38. Outcomes following intravenous bisphosphonate infusion in pediatric patients: A 7-year retrospective chart review.
Nasomyont N; Hornung LN; Gordon CM; Wasserman H
Bone; 2019 Apr; 121():60-67. PubMed ID: 30616029
[TBL] [Abstract][Full Text] [Related]
39. Long-term follow-up of patients on drug holiday from bisphosphonates: real-world setting.
Chiha M; Myers LE; Ball CA; Sinacore JM; Camacho PM
Endocr Pract; 2013; 19(6):989-94. PubMed ID: 24013976
[TBL] [Abstract][Full Text] [Related]
40. Denosumab-Induced Hypocalcemia and Hyperparathyroidism in de novo Kidney Transplant Recipients.
Cianciolo G; Tondolo F; Barbuto S; Iacovella F; Zavatta G; Altieri P; Grandinetti V; Comai G; Cozzolino M; La Manna G
Am J Nephrol; 2021; 52(8):611-619. PubMed ID: 34518468
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
